Thrombopoietic Compounds for Bone Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current orthopedic practices face challenges in achieving bone union and healing segmental defects without causing donor site morbidity, as existing methods like autografting are painful and costly, and alternative biologics like BMPs can lead to heterotopic bone formation and high expenses.
Innovation Solution
The use of thrombopoietic compounds such as thrombopoietin (TPO) and megakaryocyte growth and development factor (MGDF) to promote bone healing, combined with biodegradable scaffolds and other growth factors like BMP-2, to enhance bone regeneration and reduce heterotopic bone formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autografting is used to achieve bone union, then bone healing is promoted, but donor site morbidity and pain occur
Solution Approach 1:
The patent extracts the beneficial osteoinductive properties from autograft bone and isolates them in the form of bone morphogenetic proteins (BMPs). These proteins can then be delivered to the fracture site without requiring actual bone harvesting from the patient, thus separating the therapeutic effect from the harmful donor site morbidity.
Solution Approach 2:
The patent uses BMPs as intermediary substances that mediate the bone healing process. Instead of directly transplanting living bone tissue (which causes donor site pain), the BMP proteins serve as intermediaries that stimulate endogenous bone formation, achieving the same therapeutic goal without the harmful side effects.
2Reliability
If BMPs are used to promote bone healing, then bone union is achieved, but heterotopic bone formation occurs
Solution Approach 1:
The patent employs localized delivery systems such as collagen sponges and hydroxyapatite beads that concentrate BMP activity specifically at the fracture site. This localized delivery ensures that bone formation occurs only where needed (at the fracture gap) rather than in surrounding soft tissues, thereby preventing heterotopic bone formation while maintaining effective bone union.
Solution Approach 2:
The patent controls the dosage, release rate, and spatial distribution of BMPs to optimize therapeutic outcomes. By adjusting these parameters—using lower doses delivered over extended periods through controlled-release carriers—the patent achieves effective bone healing while minimizing the risk of heterotopic ossification that occurs with higher single-dose administrations.
3Quantity of substance
If donor bone harvesting is performed, then bone graft material is obtained, but patient pain and additional surgery are required
Solution Approach 1:
The patent creates a functional copy of autograft bone's therapeutic properties through purified BMP proteins. Instead of physically harvesting and transplanting actual bone tissue, the patent uses recombinant BMP proteins that replicate the osteoinductive effects of autograft, eliminating the need for donor site surgery while providing equivalent or superior bone healing stimulation.
Solution Approach 2:
The patent transforms the bone graft delivery system from requiring surgical harvesting of large bone pieces to administering controlled amounts of protein factors through minimally invasive techniques. This parameter change in delivery method converts a complex two-site surgical procedure into a single-site intervention with significantly reduced operative time and patient morbidity.
Data Source
AI summary
A method for treating a defect site in a living bone of an animal by applying an exogenous compound having thrombopoietic activity to the defect site in an amount effective to induce thrombopoiesis. The exogenous compound activates a thrombopoietin receptor, leading to accelerated bone formation at the defect site. Also provided is a method for repairing a segmental bone defect in an animal bone by inserting into the segmental bone defect a biodegradable bone repair scaffold that contains a compound having thrombopoietic activity. The compound activates a thrombopoietin receptor and accelerates bone formation such that bridging occurs at the segmental bone defect.